Nuvo Pharmaceuticals Inc. provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. More Details
Slightly overvalued with imperfect balance sheet.
Share Price & News
How has Nuvo Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRV is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: MRV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
7 Day Return
1 Year Return
Return vs Industry: MRV exceeded the Canadian Pharmaceuticals industry which returned 37.2% over the past year.
Return vs Market: MRV exceeded the Canadian Market which returned 29.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Nuvo Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StNuvo Pharmaceuticals Inc.'s (TSE:MRV) CEO Might Not Expect Shareholders To Be So Generous This Year
5 months ago | Simply Wall StThese 4 Measures Indicate That Nuvo Pharmaceuticals (TSE:MRV) Is Using Debt Extensively
Is Nuvo Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MRV (CA$1.21) is trading below our estimate of fair value (CA$28.62)
Significantly Below Fair Value: MRV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MRV is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: MRV is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MRV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MRV is overvalued based on its PB Ratio (5x) compared to the CA Pharmaceuticals industry average (2.7x).
How is Nuvo Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MRV's forecast earnings growth is above the savings rate (1.5%).
Earnings vs Market: Insufficient data to determine if MRV's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MRV's revenue (10.9% per year) is forecast to grow faster than the Canadian market (5.2% per year).
High Growth Revenue: MRV's revenue (10.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MRV's Return on Equity is forecast to be high in 3 years time
How has Nuvo Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRV is currently unprofitable.
Growing Profit Margin: MRV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MRV is unprofitable, and losses have increased over the past 5 years at a rate of 57.8% per year.
Accelerating Growth: Unable to compare MRV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).
Return on Equity
High ROE: MRV has a negative Return on Equity (-747.12%), as it is currently unprofitable.
How is Nuvo Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MRV's short term assets (CA$44.5M) exceed its short term liabilities (CA$22.6M).
Long Term Liabilities: MRV's short term assets (CA$44.5M) do not cover its long term liabilities (CA$124.4M).
Debt to Equity History and Analysis
Debt Level: MRV's debt to equity ratio (3678.1%) is considered high.
Reducing Debt: MRV's debt to equity ratio has increased from 0% to 3678.1% over the past 5 years.
Debt Coverage: MRV's debt is well covered by operating cash flow (22.3%).
Interest Coverage: MRV's interest payments on its debt are not well covered by EBIT (1x coverage).
What is Nuvo Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MRV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MRV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRV's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Jesse F. Ledger has been the Chief Executive Officer of Nuvo Pharmaceuticals Inc. since November 21, 2017 and as its President since November 15, 2016. Mr. Ledger served as Vice President of Business D...
CEO Compensation Analysis
Compensation vs Market: Jesse's total compensation ($USD459.58K) is above average for companies of similar size in the Canadian market ($USD167.36K).
Compensation vs Earnings: Jesse's compensation has been consistent with company performance over the past year.
Experienced Board: MRV's board of directors are seasoned and experienced ( 15.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MRV insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Nuvo Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Nuvo Pharmaceuticals Inc.
- Ticker: MRV
- Exchange: TSX
- Founded: 1983
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$13.780m
- Shares outstanding: 11.39m
- Website: https://www.miravohealthcare.com
Number of Employees
- Nuvo Pharmaceuticals Inc.
- 6733 Mississauga Road
- Suite 800
- L5N 6J5
Nuvo Pharmaceuticals Inc. provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Productio...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/04 22:52|
|End of Day Share Price||2021/08/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.